NEW YORK (GenomeWeb) – University of Maryland startup Biomecite Diagnostics has exclusively optioned the rights from UM Baltimore to develop molecular diagnostics to detect inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

The deal between Biomecite and University of Maryland Ventures covers technology developed by Florian Fricke and James White at the University of Maryland School of Medicine's Institute for Genome Sciences. The technology links distinctive genomic variants in the human gut microbiome to the two related, but unique forms of IBD.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.